The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer

Epigenomics

Volumn 8, Issue 5, 2016, Pages 721-731

  Crea, Francesco ^a,b   Venalainen, Erik ^a   Ci, Xinpei ^a,c   Cheng, Hongwei ^a,c   Pikor, Larissa ^a   Parolia, Abhijit ^a   Xue, Hui ^a   Nur Saidy, Nur Ridzwan ^a   Lin, Dong ^a,c   Lam, Wan ^a   Collins, Colin ^c   Wang, Yuzhuo ^a,c  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b OPEN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

epigenetic noncoding interactome; long noncoding RNAs; MIAT; neuroendocrine prostate cancer; Polycomb; transdifferentiation

Indexed keywords

ANDROGEN RECEPTOR; CHROMOGRANIN A; CYTOKERATIN 18; CYTOKERATIN 4; CYTOKERATIN 5; CYTOKERATIN 8; LONG UNTRANSLATED RNA; MICRORNA; NEUROPEPTIDE; POLYCOMB GROUP PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P63; SYNAPTOPHYSIN; UNTRANSLATED RNA; MIAT LONG NON-CODING RNA; TUMOR MARKER;

BASAL CELL; CANCER GROWTH; CANCER RESISTANCE; CELL PLASTICITY; CELL TRANSDIFFERENTIATION; CLINICAL FEATURE; CONTROLLED STUDY; EPIGENETIC NONCODING INTERACTOME; EPIGENETICS; EVIDENCE BASED PRACTICE; GENE EXPRESSION; GENE INTERACTION; GENE TARGETING; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; NEUROENDOCRINE PROSTATE CANCER; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UPREGULATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR;

BIOMARKERS, TUMOR; CELL TRANSDIFFERENTIATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEUROENDOCRINE TUMORS; POLYCOMB-GROUP PROTEINS; PROSTATIC NEOPLASMS; RNA, LONG NONCODING;

EID: 84970016347     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.16.6     Document Type: Review

References (99)

1. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev. 14(19), 2410-2434 (2000
2. Ousset M, Van Keymeulen A, Bouvencourt G, et al. Multipotent and unipotent progenitors contribute to prostate postnatal development. Nat. Cell Biol. 14(11), 1131-1138 (2012
3. Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am. J. Clin. Exp. Urol. 2(4), 273-285 (2014
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011
5. Caicoya M. Prostate cancer screening in Europe. Lancet 385(9977), 1507 (2015
6. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24(18), 1967-2000 (2010
7. Yuan X, Cai C, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 33(22), 2815-2825 (2014
8. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187-1197 (2012
9. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled Phase 3 study. Lancet Oncol. 13(10), 983-992 (2012
10. Berman-Booty LD, Knudsen KE. Models of neuroendocrine prostate cancer. Endocr. Relat. Cancer 22(1), R33-R49 (2015
11. Komiya A, Yasuda K, Watanabe A, Fujiuchi Y, Tsuzuki T, Fuse H. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients. Mol. Clin. Oncol. 1(2), 257-262 (2013
12. Zhang X, Coleman IM, Brown LG, et al. SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer. Clin. Cancer Res. 21(20), 4698-4670 (2015
13. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod. Pathol. 24(6), 820-828 (2011
14. Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 38(6), 756-767 (2014
15. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am. J. Transl. Res. 1(2), 148-162 (2009
16. Okamoto R, Matsumoto K, Fukuzaki H, Teranobu O, Sumiya Y. [Backache, headache, pyrexia, systemic edema and numbness of extremities (serum reactions and serum protein freactionation): (periarteritis nodosa)]. Nihon Rinsho 35(Suppl. 2), 3022-3023, 3384-3025 (1977
17. Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J. Natl Compr. Canc. Netw. 12(5), 719-726 (2014
18. Marcus DM, Goodman M, Jani AB, Osunkoya AO, Rossi PJ. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis. 15(3), 283-288 (2012
19. Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-A systematic review and pooled analysis. J. Clin. Oncol. 32(30), 3383-3390 (2014
20. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum. Pathol. 41(6), 781-793 (2010
21. Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castration-resistant prostate cancer. Clin. Cancer Res. 20(11), 2846-2850 (2014
22. Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc. Natl Acad. Sci. USA 95(26), 15382-15387 (1998
23. Terry S, Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front. Oncol. 4, 60 (2014
24. Wang ZA, Toivanen R, Bergren SK, Chambon P, Shen MM. Luminal cells are favored as the cell of origin for prostate cancer. Cell Rep. 8(5), 1339-1346 (2014
25. Santoni M, Conti A, Burattini L, et al. Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochim. Biophys. Acta 1846(2), 630-637 (2014
26. Clermont PL, Lin D, Crea F, et al. Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin. Epigenetics 7(1), 40 (2015
27. Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod. Pathol. 24(8), 1120-1127 (2011
28. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1(6), 487-495 (2011
29. Hansel DE, Nakayama M, Luo J, et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 69(6), 603-609 (2009
30. Scheble VJ, Braun M, Wilbertz T, et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology 56(7), 937-943 (2010
31. Kadakia KC, Tomlins SA, Sanghvi SK, et al. Comprehensive serial molecular profiling of an "N of 1" exceptional nonresponder with metastatic prostate cancer progressing to small cell carcinoma on treatment. J. Hematol. Oncol. 8(1), 109 (2015
32. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr. Relat. Cancer 14(3), 531-547 (2007
33. Buttigliero C, Tucci M, Bertaglia V, et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat. Rev. 41(10), 884-892 (2015
34. Logothetis CJ, Gallick GE, Maity SN, et al. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 3(8), 849-861 (2013
35. Mosquera JM, Beltran H, Park K, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15(1), 1-10 (2013
36. Lin D, Wyatt AW, Xue H, et al. High fidelity patientderived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74(4), 1272-1283 (2014
37. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 9(11), 773-784 (2009
38. Koppens M, Van Lohuizen M. Context-dependent actions of Polycomb repressors in cancer. Oncogene doi: 10.1038/ onc.2015.195 (2015) (Epub ahead of print
39. Bernstein E, Duncan EM, Masui O, Gil J, Heard E, Allis CD. Mouse Polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol. Cell Biol. 26(7), 2560-2569 (2006
40. Simon JA, Kingston RE. Mechanisms of Polycomb gene silencing: knowns and unknowns. Nat. Rev. Mol. Cell Biol. 10(10), 697-708 (2009
41. Di Croce L, Helin K. Transcriptional regulation by Polycomb group proteins. Nat. Struct. Mol. Biol. 20(10), 1147-1155 (2013
42. Zhou W, Zhu P, Wang J, et al. Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation. Mol. Cell 29(1), 69-80 (2008
43. Chang X, Sun Y, Han S, Zhu W, Zhang H, Lian S. MiR-203 inhibits melanoma invasive and proliferative abilities by targeting the Polycomb group gene BMI1. Biochem. Biophys. Res. Commun. 456(1), 361-366 (2015
44. Chen DL, Zhang DS, Lu YX, et al. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. Oncotarget 6(13), 10868-10879 (2015
45. Crea F, Hurt EM, Mathews LA, et al. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol. Cancer 10, 40 (2011
46. Zhang Q, Padi SK, Tindall DJ, Guo B. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell Death Dis. 5, e1486 (2014
47. Fan TY, Wang H, Xiang P, et al. Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma. Int. J. Clin. Exp. Pathol. 7(10), 6662-6670 (2014
48. Liu L, Guo J, Yu L, et al. miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumour Biol. 35(12), 12619-12626 (2014
49. Corley M, Kroll KL. The roles and regulation of Polycomb complexes in neural development. Cell Tissue Res. 359(1), 65-85 (2015
50. Egan CM, Nyman U, Skotte J, et al. CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and Polycomb gene repression. Dev. Cell 26(3), 223-236 (2013
51. Zhang J, Ji F, Liu Y, et al. Ezh2 regulates adult hippocampal neurogenesis and memory. J. Neurosci. 34(15), 5184-5199 (2014
52. Akamatsu S, Wyatt AW, Lin D, et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep. 12(6), 922-936 (2015
53. Lin D, Dong X, Wang K, et al. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget 6(3), 1806-1820 (2015
54. Tsai MC, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 329(5992), 689-693 (2010
55. Conaco C, Otto S, Han JJ, Mandel G. Reciprocal actions of REST and a microRNA promote neuronal identity. Proc. Natl Acad. Sci. USA 103(7), 2422-2427 (2006
56. Svensson C, Ceder J, Iglesias-Gato D, et al. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res. 42(2), 999-1015 (2014
57. Kanwal R, Gupta K, Gupta S. Cancer epigenetics: an introduction. Methods Mol. Biol. 1238, 3-25 (2015
58. Ponting CP, Belgard TG. Transcribed dark matter: meaning or myth?. Hum. Mol. Genet. 19(R2), R162-R168 (2010
59. Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447(7146), 799-816 (2007
60. Struhl K. Transcriptional noise and the fidelity of initiation by RNA polymerase II. Nat. Struct. Mol. Biol. 14(2), 103-105 (2007
61. Ponjavic J, Ponting CP, Lunter G. Functionality or transcriptional noise?. Evidence for selection within long noncoding RNAs. Genome Res. 17(5), 556-565 (2007
62. Qu Z, Adelson DL. Evolutionary conservation and functional roles of ncRNA. Front. Genet. 3, 205 (2012
63. Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature 482(7385), 339-346 (2012
64. Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142(3), 409-419 (2010
65. Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod. Pathol. 26(2), 155-165 (2013
66. Crea F, Clermont PL, Parolia A, Wang Y, Helgason CD. The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer Metastasis Rev. 33(1), 1-16 (2014
67. Utikal J, Abba M, Novak D, Moniuszko M, Allgayer H. Function and significance of MicroRNAs in benign and malignant human stem cells. Semin. Cancer Biol. 35, 200-211 (2015
68. Zhang CL, Zhu KP, Shen GQ, Zhu ZS. A long noncoding RNA contributes to doxorubicin resistance of osteosarcoma. Tumour Biol. doi: 10.1007/s13277-015-4130-7 (2015) (Epub ahead of print
69. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther. 17(8), 523-531 (2010
70. Donzelli S, Mori F, Biagioni F, et al. MicroRNAs: short noncoding players in cancer chemoresistance. Mol. Cell Ther. 2, 16 (2014
71. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15(8), 509-524 (2014
72. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11(9), 597-610 (2010
73. Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer - a brief overview. Adv. Biol. Regul. 57, 1-9 (2015
74. Lapuk AV, Wu C, Wyatt AW, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J. Pathol. 227(3), 286-297 (2012
75. Yoo AS, Staahl BT, Chen L, Crabtree GR. MicroRNAmediated switching of chromatin-remodelling complexes in neural development. Nature 460(7255), 642-646 (2009
76. Zhao C, Sun G, Li S, et al. MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. Proc. Natl Acad. Sci. USA 107(5), 1876-1881 (2010
77. Wu D, Yu S, Jia L, et al. Orphan nuclear receptor TLX functions as a potent suppressor of oncogene-induced senescence in prostate cancer via its transcriptional coregulation of the CDKN1A (p21WAF1/CIP1) and SIRT1 genes. J. Pathol. 236(1), 103-115 (2015
78. Dossing KB, Binderup T, Kaczkowski B, et al. Downregulation of miR-129-5p and the let-7 family in neuroendocrine tumors and metastases leads to up-regulation of their targets Egr1, G3bp1, Hmga2 and Bach1. Genes 6(1), 1-21 (2014
79. Chinnaiyan AM, Prensner JR. The emergence of lncRNAs in cancer biology. Cancer Discov. 1(5), 391-407 (2011
80. Joh RI, Palmieri CM, Hill IT, Motamedi M. Regulation of histone methylation by noncoding RNAs. Biochim. Biophys. Acta 1839(12), 1385-1394 (2014
81. Quinodoz S, Guttman M. Long noncoding RNAs: an emerging link between gene regulation and nuclear organization. Trends Cell Biol. 24(11), 651-663 (2014
82. Vance KW, Ponting CP. Transcriptional regulatory functions of nuclear long noncoding RNAs. Trends Genet. 30(8), 348-355 (2014
83. Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatinmodifying complexes and affect gene expression. Proc. Natl Acad. Sci. USA 106(28), 11667-11672 (2009
84. Nagano T, Mitchell JA, Sanz LA, et al. The air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 322(5908), 1717-1720 (2008
85. Pandey RR, Mondal T, Mohammad F, et al. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol. Cell 32(2), 232-246 (2008
86. Guo X, Deng L, Deng K, et al. Pseudogene PTENP1 suppresses gastric cancer progression by modulating PTEN. Anticancer Agents Med. Chem. 16(4), 456-464 (2016
87. Hu L, Ye H, Huang G, et al. Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. Tumour Biol. doi: 10.1007/s13277-015-4130-7 (2015) (Epub ahead of print
88. Tsang WP, Ng EK, Ng SS, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 31(3), 350-358 (2010
89. Prensner JR, Iyer MK, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet. 45(11), 1392-1398 (2013
90. Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 29(8), 742-749 (2011
91. Shen XH, Qi P, Du X. Long non-coding RNAs in cancer invasion and metastasis. Mod. Pathol. 28(1), 4-13 (2015
92. Crea F, Danesi R, Farrar WL. Cancer stem cell epigenetics and chemoresistance. Epigenomics 1(1), 63-79 (2009
93. Iyer MK, Niknafs YS, Malik R, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat. Genet. 47(3), 199-208 (2015
94. Barry G, Briggs JA, Vanichkina DP, et al. The long noncoding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-Associated alternative splicing. Mol. Psychiatry 19(4), 486-494 (2014
95. Living Tumor Laboratory. www.livingtumorlab.com 96 Ensembl Genome Browser. http://uswest.ensembl.org 97 Tan HL, Sood A, Rahimi HA, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 20(4), 890-903 (2014
96. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1), 11-22 (2010
97. Chang CJ, Yang JY, Xia W, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 19(1), 86-100 (2011
98. Lugnani F, Simone G, Biava PM, Ablin RJ. The role of neuroendocrine cells in prostate cancer: a comprehensive review of current literature and subsequent rationale to broaden and integrate current treatment modalities. Curr. Med. Chem. 21(9), 1082-1092 (2014
99. Mercer TR, Qureshi IA, Gokhan S, et al. Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation. BMC Neurosci. 11, 14 (2010